All news

Sabra Health Care REIT gets fresh valuation review

Alpha Vantage · AD HOC NEWS · · AI-summarised by FinFlash

Sabra Health Care REIT received a fresh valuation review setting fair value at USD 22.79, emphasizing managed senior housing, portfolio recycling and balance sheet flexibility. The company posted Q2 2026 same-store revenue growth of 8.6 percent but a negative adjusted EPS that missed consensus. Analysts hold a Moderate Buy consensus with an average price target of USD 22.23, well above the current Nasdaq price, on a 6/9/1 buy-hold-sell split.

Read original source

SBRA company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.